TABLE 1.

Details of pharmacokinetic studies^a

Study no.	No. of centers, location	Underlying diagnosis	Fluconazole dosage (mg/kg/day), route of administration	Duration or type of therapy	No. of patients	Mean age (range)	Reference
006	2, USA	Cancer chemotherapy	2, 4, or 8, i.v.	7 days	26	11.2 yr (5–15 yr)	Lee et al. (17)
018	6, USA	Oncological malignancy, with patients receiving chemotherapy, radiation, or supportive care, or HIV infection	2 or 8, p.o.	Single dose	45	2 mg, 6.3 yr; 8 mg, 5.8 yr (9 mo–13 yr)	Brammer and Coates (1)
239	1, UK	Malignant disease or BMT; expectation of neutropenia	3, p.o.b	1–41 days	16	4.6 yr (0–10 yr)	Pfizer, Inc. (21a)
241	1, France	Acquired or congenital immune deficiency syndromes	3, i.v.	Single dose	16	65.9 wk (1.6–293.1 wk)	Brammer and Coates
247	1, UK	Malignant disease or BMT; expectation of neutropenia	3, p.o.b	4–20 days	13	7.2 yr (1–12 yr)	Brammer and Coates (1)
375	1, Finland	Prematurity, very low birth weight	6 every 72 h, i.v.	2–5 doses	12	23.7 h (8.6–35.7 h)	Saxén et al. (24)

^aAbbreviations: USA, United States; UK, United Kingdom; i.v., intravenously; p.o., orally; BMT = bone marrow transplantation. 

^bSingle dose followed 48 h later by daily dosing.